Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Research into the early detection of ovarian cancer by the Ahmed group at the MRC Weatherall Institute of Molecular Medicine (MRC WIMM) receives a boost thanks to a gift of £43,000 from the Dianne Oxberry Trust.

© Dr Siobhan Ferguson & Ian Hindle (Dianne Oxberry Trust), Prof Ahmed Ahmed, Abdulkhaliq Alsaadi & Mara Artibani (Weatherall Institute of Molecular Medicine, NDWRH, Oxford University)

The donation will support doctoral candidate Abdulkhaliq Alsaadi in this research by covering the stipend and other costs associated with his final year of study, including research consumables.

More than 250,000 women around the world are diagnosed with ovarian cancer every year, with almost half dying from the disease. This makes ovarian cancer the most common cause of death from a gynaecological malignancy. Late diagnosis a key contributing factor.

At Oxford, a concerted effort is being made to better understand the origins of the disease. Led by Ahmed Ahmed, Professor of Gynaecological Oncology in the Nuffield Department of Women’s and Reproductive Health, researchers are utilising cutting-edge methodologies to classify the cells in the fallopian tube – thought to be the organ from which most ovarian cancers develop. It is hoped that this will lead to the discovery of new biomarkers that could be used for pre-cancer screening.

Read more (MRC WIMM website)

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.